抗前列腺增生药SL—89．0519—08的合成

目的：研究治疗前列腺增生的α1－受体拮抗剂SL－89．0519－08的合成路线。方法：以5－氯－2－甲氧基苯胺为原料，经环合，烃化，脱保护基和亲核取代等步骤，合成了目标化合物，同时对原料合成工艺进行了摸索。结果：合成的目标化合物经IR，^1HMNR,EI-MS和HRMS得以确证。结论：该合成工艺和路线适宜工业化生产。     

外科护理文书存在的风险及管理对策

对外科护理文书的风险细节管理中存在的问题进行阐述，提出强化外科护士的法律意识，树立风险源于细节的管理意识，保证护理文书记录的科学性、及时性、准确性及真实性，注重护患沟通，提高护理质量是降低护理风险，避免医疗纠纷发生的关键。     

放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.     

重组人血小板源性生长因子增加细胞外信号调节激酶磷酸化促进糖尿病大鼠全层皮肤缺损创面愈合

目的 在体观察重组人血小板源性生长因子（recombinant human platelet—derived growth factor，rhPDGF）促进糖尿病大鼠全层皮肤缺损创面修复可能涉及的细胞和分子机制，研究其可能涉及的信号通路。方法 26只糖尿病大鼠，每只动物背部制备4个全层皮肤缺损创面，选取其中52个创面，随机分成3组，即对照组，创面自然愈合；rhPDGF治疗组，创面rhPDGF用量为7．0μg／cm^2；赋形剂组，创面用等量赋形剂凝胶。观察治疗后3、7和14d创面肉芽形成、胶原沉积、再上皮化速率以及炎性细胞浸润情况，并采用免疫荧光和免疫组织化学技术观察创面周围和创面修复细胞内细胞外信号调节激酶1／2（extracellular signal—regulated kinase1／2，ERK1／2）磷酸化和增殖细胞核抗原（proliferative cell nuclear antigen，PCNA）的表达。结果 组织学观察，rhPDGF治疗组创面可见大量炎性细胞浸润，毛细血管胚芽及成纤维细胞明显多于另两组（P〈0．05）；胶原沉积明显，肉芽组织生长活跃，创面收缩显著，与对照组比较差异有统计学意义（P〈0．05）。免疫学研究显示，应用rhPDGF7～14d后，rhPDGF治疗组ERK1／2明显强于对照组和赋形剂组（P〈0．05）；且损伤后3～7d rhPDGF治疗组修复细胞PCNA的表达明显高于对照组和赋形剂组（P〈0．05）。结论 rhPDGF促糖尿病大鼠刨面愈合的作用部分是通过ERK1／2信号通路的磷酸化来完成的。     

PTEN基因敲除降低辐射敏感性及其机制

目的 探讨PTEN基因敲除对辐射敏感性的影响及机制。方法 采用流式细胞术检测MEF1和MEF1/PTEN^－/－细胞内ROS水平;采用Western blot方法,检测H₂O₂和DPI预处理后AKT激酶的表达变化;采用细胞克隆形成率试验分析细胞对⁶⁰Co γ射线的敏感性。结果 PTEN基因敲除后细胞ROS水平增加,辐射敏感性降低。H₂O₂和DPI预处理后影响MEF1细胞AKT激酶活性,但对MEF1/Pten^－/－细胞无影响。 结论 PTEN基因敲除阻断了ROS对AKT的介导,AKT激酶持续活化,可能是辐射敏感性降低的重要原因。     

中西医结合治疗急性冠脉综合征临床疗效观察

目的观察中西医结合治疗急性冠脉综合征（ACS）的临床疗效。方法将60例ACS患者随机分为两组。治疗组在抗血小板、抗凝、降脂、扩张冠状动脉、降压、保护血管内皮功能等常规治疗基础上服用中药复方苏欣康颗粒；对照组在常规治疗基础上加用复方丹参滴丸。2周为1个疗程，1个疗程结束后观察治疗前后临床症状、心电图、24h动态心电图变化，并判定疗效。结果经2周治疗后，治疗组总有效率（90．O％，27／30）显著高于对照组（83．3％，25／30），差异有统计学意义（P〈0．05）。治疗组临床症状的改善程度高于对照组，其中以对心悸、自汗及心肾阳虚的改善最显著（P均〈0．05）。治疗组心律失常发生率（36．7％）低于对照组（50．0％），但差异无统计学意义（P〉O．05）。结论中药复方苏欣康结合常规手段治疗ACS疗效确切，可作为治疗ACS的有效方剂。     

新生儿腹胀98例临床分析

目的：探讨新生儿腹胀的常见原因及治疗、转归。方法：对98例腹胀新生儿进行病因分类、回顾性分析治疗转归。结果：以出院诊断为标准，98例患儿中感染性疾病42例，占42．86％；早产儿生活力低下32例，占32．65％。1～3d痊愈12例，1W内痊愈81例，3例转外科治疗，2例死亡。结论：感染性疾病是新生儿腹胀的主要原因，早产儿尤其体重低下者是腹胀的高危人群。临床医师应高度重视，尽快明确原因，给予及时、合理治疗，以提高新生儿生存率。     

乳腺良恶性病变的磁共振T2*W首过灌注成像与血管生成相关性研究

Objective： To study the diagnostic value of T2^＊-weighted first-pass perfusion imaging in breast tumors. Methods： We analyzed the magnetic resonance imaging （MRI） information along with the pathological and immunohistochemistry results. Magnetic resonance imaging was performed in 28 patients with breast tumor. The time to signal intensity curves were generated according to the T2^＊-weighted first-pass perfusion imaging. The curve＇s maximal signal intensity drop rate and maximal signal intensity decrease time were analyzed and compared with the pathological diagnoses after surgery. Results： Malignant breast lesions showed higher maximal signal intensity drop rate （44.69% ± 17.07 vs. 17.22% ±7.49, P 〈 0.001） than benign lesions, but there was no significant difference of maximal signal decrease time between those two lesions （23.94 s ± 4.92 vs. 20.02 s ± 6.83, P 〉 0.05）. Conclusion： The T2^＊-weighted first-pass perfusion imaging has enough sensitivity and specificity in breast tumor diagnosis.     

当前临床正畸应予关注的几项矫正技术

口腔正畸是一门临床学科，通过基础和临床研究促使它不断得到发展，临床新技术直接推动了口腔正畸矫治水平的提高。近年来在临床口腔正畸推广应用的4项新技术——种植体支抗、自锁托槽、改进后的舌侧矫正技术和无托槽矫正技术，应该引起我们的关注。因为由此可能带来正畸发展的一个快速阶段。